- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06214819
Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.
March 20, 2024 updated by: Fundación EPIC
Randomized, Controlled, Open-label, Double-blind, Multicenter Investigation Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.
To evaluate the stent endothelialization (> 20 microns) of VIVO ISARTM versus XIENCE SkypointTM stents at 1-month (very early strut covered) at follow-up by Optical Coherence Tomography (OCT) implanted IN THE SAME PATIENT during routine clinical practice.
Study Overview
Status
Recruiting
Conditions
Detailed Description
To evaluate the stent endothelialization (> 20 microns) of VIVO ISARTM versus XIENCE SkypointTM stents at 1-month (very early strut covered) at follow-up by Optical Coherence Tomography (OCT) implanted IN THE SAME PATIENT during routine clinical practice.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: FUNDACION EPIC
- Phone Number: 0034987876135
- Email: iepic@fundacionepic.org
Study Contact Backup
- Name: BRUNO GARCIA DEL BLANCO, MD, PhD
- Phone Number: 0034932746155
- Email: brunogb51@gmail.com
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with age ≥ 18 years AND
- Patients who have signed informed consent AND
- Patients with coronary artery disease requiring percutaneous treatment with coronary stents due to de novo lesions in vessels with a diameter of reference from 2.25 mm to 4.0 mm AND
- Patients with at least 2 angiographic lesions in 2 different major coronary arteries. Or in the main branch and in one of its subsidiaries branches , as long as those are not "downstream" of the lesion from the main branch
Exclusion Criteria:
- Express refusal of the patient to participate in the study
- Patients with ST elevation Myocardial Infarction or Cardiogenic Shock
- Patients with high thrombotic content
- Pregnant or breastfeeding patients
Patients with complex PCI (Percutaneous Coronary Intervention )(defined as):
- Left main PC
- Chronic total PC occlusion
- Bifurcation lesion requiring 2-stent technique .
- Severe calcified lesion (need to use prior complex techniques of calcium modification such as intravascular lithotripsy, rotational/orbital atherectomy, laser.
- Patients with malignant neoplasms or other comorbid conditions with life expectancy <12 months
- Patients with a target lesion in a bypass graft
- Lesions due to restenosis
- Patients with PCI in the target vessel in the previous 9 months
- Patients with contraindication or difficulty to evaluate in the follow-up with OCT (renal failure, excessive tortuosity or lesions aorto-ostial)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VIVO ISAR DES in the first lesion
|
VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
|
Active Comparator: XIENCE Skypoint DES in the first lesion
|
XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of early Covered struts (≥ 20μm) at 1 month OCT after stent implantation
Time Frame: 1 month
|
Percentage of early Covered struts (≥ 20μm) at 1 month OCT after stent implantation
|
1 month
|
Percentage of stents with uncovered struts at 1 month OCT after stent implantation
Time Frame: 1 month
|
Percentage of stents with uncovered struts (0μm) at 1 month OCT after stent implantation
|
1 month
|
Mean thickness of struts tissue coverage at 1 month OCT after stent implantation
Time Frame: 1 month
|
Mean thickness of struts tissue coverage at 1 month OCT after stent implantation
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of malapposition of stent at 1 month OCT after stent implantation
Time Frame: 1 month
|
Percentage of malapposition of stent at 1 month OCT after stent implantation
|
1 month
|
Percentage of covered struts at 1 months OCT after stent implantation
Time Frame: 1 month
|
Percentage of covered struts at 1 months OCT after stent implantation
|
1 month
|
All-Cause Death Rate at 6 months
Time Frame: 6 months
|
All-Cause Death Rate at 6 months
|
6 months
|
Cardiac Death Rate at 6 months
Time Frame: 6 months
|
Cardiac Death Rate at 6 months
|
6 months
|
Myocardial Infarction Rate at 6 months
Time Frame: 6 months
|
Myocardial Infarction Rate at 6 months
|
6 months
|
Target vessel revascularization Rate at 6 months
Time Frame: 6 months
|
Target vessel revascularization Rate at 6 months
|
6 months
|
Neointimal Healing Score (NHC) by OCT at 1 month
Time Frame: 1 months
|
The NHS is then calculated as follows:
|
1 months
|
Percentage of malapposed total struts at 1 month
Time Frame: 1 month
|
Percentage of malapposed total struts at 1 month
|
1 month
|
Percentage of malapposed scaffold struts over side branch at 1 month
Time Frame: 1 month
|
Strut malapposition: Measured maximum distance ≥100 μm between the strut surface and adjacent vessel surface by OCT, considering thickness of scaffold, was defined as malapposition.
As a result, scaffold malapposition is defined as the presence of any malapposed struts.
The ratio of malapposed struts (% malapposed strut) was the ratio of malapposed struts from total analyzable struts.
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Koppara T, Tada T, Xhepa E, Kufner S, Byrne RA, Ibrahim T, Laugwitz KL, Kastrati A, Joner M. Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. Int J Cardiol. 2018 May 1;258:42-49. doi: 10.1016/j.ijcard.2018.01.011.
- Asano T, Jin Q, Katagiri Y, Kogame N, Takahashi K, Chang CC, Chichareon P, Wang C, Shi B, Su X, Fu G, Wu Y, Zhou X, Yuan Z, Wykrzykowska JJ, Piek JJ, Serruys PW, Onuma Y, Chen Y. A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. EuroIntervention. 2018 Dec 20;14(12):e1306-e1315. doi: 10.4244/EIJ-D-18-00461.
- Andreasen LN, Balleby IR, Barkholt TO, Hebsgaard L, Terkelsen CJ, Holck EN, Jensen LO, Maeng M, Dijkstra J, Antonsen L, Kristensen SD, Tu S, Lassen JF, Christiansen EH, Holm NR. Early healing after treatment of coronary lesions by thin strut everolimus, or thicker strut biolimus eluting bioabsorbable polymer stents: The SORT-OUT VIII OCT study. Catheter Cardiovasc Interv. 2023 Mar;101(4):787-797. doi: 10.1002/ccd.30579. Epub 2023 Feb 5.
- Otaegui Irurueta I, Gonzalez Sucarrats S, Barron Molina JL, Perez de Prado A, Massotti M, Carmona Ramirez MA, Marti G, Bellera N, Serra B, Serra V, Domingo E, Lopez-Benito M, Sabate M, Ferreira Gonzalez I, Garcia Del Blanco B. Can an ultrathin strut stent design and a polymer free, proendothelializing probucol matrix coating improve early strut healing? The FRIENDLY-OCT trial. An intra-patient randomized study with OCT, evaluating early strut coverage of a novel probucol coated polymer-free and ultra-thin strut sirolimus-eluting stent compared to a biodegradable polymer sirolimus-eluting stent. Int J Cardiol. 2022 Aug 1;360:13-20. doi: 10.1016/j.ijcard.2022.04.043. Epub 2022 Apr 25.
- Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Polymerfree sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISARTEST 5) trial. Circulation. 2 de agosto de 2011;124(5):624-32. 18. Kufner S, Sorges J, Mehilli J, Cassese S, Repp J, Wiebe J, et al. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. JACC Cardiovasc Interv. 25 de abril de 2016;9(8):784-92.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 20, 2024
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
January 31, 2026
Study Registration Dates
First Submitted
December 13, 2023
First Submitted That Met QC Criteria
January 17, 2024
First Posted (Actual)
January 22, 2024
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIC31-PRO-HEAL TRIAL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
-
Fundacja Ośrodek Badań MedycznychCompletedMyocardial InfarctionPoland, Slovenia